Meiji Holdings Co., Ltd. · TSE:2269

Meiji — Investor Day (June 2021)

20 slides from Meiji's investor day presentation, Jun 15, 2021

  1. Slide 1: IR Day (Business Strategy Conference) Pharmaceutical segment

    IR Day (Business Strategy Conference) Pharmaceutical segment June 15, 2021 0 © Meiji Holdings Co., Ltd. All rights reserved. Confidential

  2. Slide 2: Summary of 2020 Medium-Term Business Plan

    Summary of 2020 Medium-Term Business Plan 1 © Meiji Holdings Co., Ltd. All rights reserved. Confidential

  3. Slide 3: Summary Results of 2020 Medium-Term Business Plan-1

    Summary Results of 2020 Medium-Term Business Plan-1 Operating Profit (JPY bn) CAGR 20.2% Initial Plan 19.1 15.9 15.0 14.2 11.0 (JPY bn) FY 2017 FY 2018 FY 2019 FY 2020 FY 2020 Net sales 168.4 198.6 204.3 193.6 190.0 Op. profit margin 6.5% 7.2% 7.8% 9.9% 7.9% Net sales of 39.4 41.0 43.5 37.6 52.0 ove

  4. Slide 4: Summary Results of 2020 Medium-Term Business Plan-2

    Summary Results of 2020 Medium-Term Business Plan-2  What we have achieved  Acquired KM Biologics and expanded into vaccine business  CMO/CDMO business in Medreich grew steadily, gradually expanding business for Japan  Expanded sales of ASEAN business  Strengthened pipeline (In licensed KD025 a

  5. Slide 5: Efforts against COVID-19

    Efforts against COVID-19 1. Research and development Theme Public funds Development of inactivate vaccine against Development of Vaccine 1 AMED Against COVID-19 COVID-19 Development of COVID-19 therapeutic agent Cyclic Innovation for and antivirus drug based on the Ōmura natural 2 AMED Clinical Empo

  6. Slide 6: 2023 Medium-Term Business Plan

    2023 Medium-Term Business Plan 5 © Meiji Holdings Co., Ltd. All rights reserved. Confidential

  7. Slide 7: Rebuild Business Portfolio

    Rebuild Business Portfolio  Focus our management resources on infectious disease, our specialized area, considering market environment and rapid changes of technological innovation  Review business portfolio using ROIC effectively Disclosure unit Business management unit 1) Brand-name drugs Pharma

  8. Slide 8: Product Share in Infectious Disease by volume

    Product Share in Infectious Disease by volume  Antibacterial, injection 66.9% 68.2% 51.2% Vancomycin Sulbacillin Tazopipe  Human vaccine 24.8% 77.1% 30.1% Hepatitis Influenza DTaP-IPV vaccine type vaccine HA vaccine A and B Copyright © 2021 IQVIA. Reprinted with permission 7 © Meiji Holdings Co.,

  9. Slide 9: Business Strategy: Human Vaccines

    Business Strategy: Human Vaccines Integrate business operations of Meiji Seika Pharma and KM Biologics Net sales (JPY bn)*  Improve R&D collaboration  Enhance supply management integrating production and sales 45.9 43.9 41.6  Progress product development  Inactivated vaccine FY 2020 FY 2021 .. F

  10. Slide 10: Business Strategy: Domestic Ethical Pharmaceuticals -1

    Business Strategy: Domestic Ethical Pharmaceuticals -1 Sales of pharmaceuticals in Brand-name drugs Japan (JPY bn)*1 Promote structural reform and CAGR 4.7% maximize sales of mainstay products  Reduce fixed cost by promoting structural reform 97.5 104.9 91.4  Reorganize sales offices  Work-style

  11. Slide 11: Business Strategy: Domestic Ethical Pharmaceuticals -2

    Business Strategy: Domestic Ethical Pharmaceuticals -2 Long-listed/ Generic Drugs Better quality assurance and selection and concentration of product portfolio  Strengthen quality management for better quality assurance  Improve profitability: Decrease SKUs  Establish business model: Manufacture

  12. Slide 12: Business Strategy: Overseas Ethical Pharmaceuticals

    Business Strategy: Overseas Ethical Pharmaceuticals Sales of own products Net sales (JPY bn)* CAGR 7.9% Build product strategy proper for each country  Expand sales of MEIACT, antibiotics and 49.5 44.4 ADANT, hyaluronic acid preparation 39.4  Develop brand-name drugs FY 2020 FY 2021 .. FY 2023 CMO

  13. Slide 13: Business Strategy: Agricultural Chemicals and Veterinary drugs

    Business Strategy: Agricultural Chemicals and Veterinary drugs Agricultural Chemicals Expand sales of mainstay products in Net sales (JPY bn)* Japan and develop overseas business CAGR15.6%  Ensure stable procurement of important raw material  Expand sales of mainstay products in Japan 22.8 26.1 16

  14. Slide 14: Target for Net Sales and Operating Profit

    Target for Net Sales and Operating Profit Net sales (JPY bn) * CAGR 4.7% 182.1 194.5 209.0 FY 2020 FY 2021 ・・ FY 2023 FY2021 Analysis of Operating Profit (JPY bn) FY2023 Analysis of Operating Profit (JPY bn) Increase in sales of FY 2020 mainstay products and 19.1 one-time revenues FY 2020 19.1 from

  15. Slide 15: References

    References 14 © Meiji Holdings Co., Ltd. All rights reserved. Confidential

  16. Slide 16: Pharmaceutical Segment Business Plan for FY 2021 and FY 2023

    Pharmaceutical Segment Business Plan* for FY 2021 and FY 2023 (JPY bn) FY 2021 FY 2023 YoY Change vs. FY 2020 Net sales 97.5 +6.7% 104.9 +14.8% Domestic ethical pharmaceuticals Op. profit 6.4 +14.3% 3.5 -37.5% Net sales 44.4 +12.7% 49.5 +25.6% Overseas ethical pharmaceuticals Op. profit 4.0 +5.3% 6.

  17. Slide 17: R&D Pipeline-1

    R&D Pipeline-1 ■Japan ■Overseas R&D Pipeline (◆: discovered in-house) FY 2020 FY 2021 FY 2022 Infectious diseases ME1100 Arbekacin inhalation [HABP/VABP] ◆ P Ib PI OP0595 Nacubactam [β-lactamase inhibitor] ◆ with β-Lactams disorders CNS ME2112 Ziprasidone [Antipsychotic] Phase III [Relapsed or refra

  18. Slide 18: R&D Pipeline-2

    R&D Pipeline-2 ■Japan ■Overseas R&D Pipeline(◆: discovered in-house) FY 2020 FY 2021 FY 2022 Phase III Apply KD-370 [Pentavalent vaccine against diphtheria, tetanus, pertussis, polio, and haemophilus influenza type b] ◆ Phase II Human vaccines KD-382 [Quadrivalent vaccine against dengue fever] ◆ Pha

  19. Slide 19: R&D Pipeline-3

    R&D Pipeline-3 ■Japan ■Overseas R&D Pipeline (◆: discovered in-house) FY 2020 FY 2021 FY 2022 Agricultural chemicals Approved ME5382 [Insecticide/Flupyrimin] ◆ ME5343 [Insecticide] Licensing agreement with BASF ◆* Approved ANM-138 [Insecticide] Joint development with Nippon Kayaku ◆ Approved Approve

  20. Slide 20:  Information in this material is not intended to solicit sale or purchase of

     Information in this material is not intended to solicit sale or purchase of shares in Meiji Holdings.  Business forecasts and other forward-looking statements are based on information available at the time of the release of this presentation and reasonable assumptions made by the Company. Actual

Meiji Holdings — Investor Day (June 2021) on 6ix